GLP-3 RT10MG

Retatrutide is an experimental multi-receptor agonist peptide developed for treating obesity and type 2 diabetes. It activates GLP-1, GIP, and glucagon receptors—a “triple agonist” approach that enhances metabolic effects beyond current GLP-1 drugs.

Key points:

• Mechanism: Stimulates GLP-1 and GIP receptors to improve insulin secretion and satiety, while glucagon receptor activation boosts energy expenditure.

• Effects: In clinical trials, it led to remarkable weight loss (up to ~24% of body weight), improved glucose control, and reduced liver fat.

• Side effects: Similar to GLP-1 agonists—nausea, vomiting, and gastrointestinal discomfort—but generally dose-dependent and manageable. 

Shipped in 3ml vial lyophilized powder.

Not for human consumption.

For research use only. 

Labeled and packaged locally in Houston, Texas